Martin Tolar Selected Research

Amyloid Plaque

2/2024	The Single Toxin Origin of Alzheimer's Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention.
6/2021	Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression.
12/2020	Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Martin Tolar Research Topics

Disease

8	Alzheimer Disease (Alzheimer's Disease) 02/2024 - 06/2017
3	Amyloid Plaque 02/2024 - 12/2020
3	Disease Progression 02/2024 - 12/2020
3	Neurodegenerative Diseases (Neurodegenerative Disease) 02/2024 - 06/2017
2	Cognitive Dysfunction 01/2020 - 01/2011
1	Dementia (Dementias) 02/2024
1	Edema (Dropsy) 12/2020
1	Atrophy 01/2020
1	Cerebral Cortical Thinning 01/2020
1	Vomiting 01/2018
1	Nausea 01/2018
1	Memory Disorders (Memory Loss) 01/2018

Drug/Important Bio-Agent (IBA)

5	Amyloid (Amyloid Fibrils)IBA 02/2024 - 01/2018
4	Amyloid beta-PeptidesIBA 06/2021 - 06/2017
4	tramiprosateIBA 01/2020 - 06/2017
3	ALZ-801IBA 12/2020 - 01/2018
2	Proteins (Proteins, Gene)FDA Link 02/2024 - 06/2017
2	Apolipoprotein E4IBA 06/2021 - 12/2020
2	ApolipoproteinsIBA 06/2021 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 12/2020 - 01/2020
2	Apolipoproteins E (ApoE)IBA 01/2020 - 01/2011
1	PrionsIBA 02/2024
1	aducanumabIBA 12/2020
1	lecanemabIBA 12/2020
1	gantenerumabIBA 12/2020
1	ProdrugsIBA 01/2018

Therapy/Procedure

2	Therapeutics 11/2020 - 06/2017